Through a structure-based molecular hybridization and bioisosterism approach, a series of novel 2-(pyridin-3-yloxy)acetamide derivatives were designed, synthesized, and evaluated for their anti-HIV activities in MT-4 cell cultures. Biological results showed that three compounds (Ia, Ih, and Ij) exhibited moderate inhibitory activities against wild-type (wt) HIV-1 strain (IIIB ) with EC50 values ranging from 8.18 μm to 41.52 μm. Among them, Ij was the most active analogue possessing an EC50 value of 8.18 μm. To further confirm the binding target, four compounds were selected to implement an HIV-1 RT inhibitory assay. In addition, preliminary structure-activity relationship (SAR) analysis and some predicted physicochemical properties of three...
Novel 2-aryalkylthio-4-amino-6-benzylpyrimidines (3a-i), which can be considered as S-DABO and TMC-1...
A series of 2-(4-(naphthalen-2-yl)-1,2,3-thiadiazol-5-ylthio)acetamide (TTA) derivatives were synthe...
Background: Despite the progress in the discovery of antiretroviral compounds for treating HIV-1 inf...
The present work is an extension of our ongoing efforts towards the development and identification o...
A series of novel 5-alkyl-6-Adamantylmethylpyrimidin-4(3H)-ones bearing various substituents at the ...
Based on crystallographic overlays of the known inhibitors TMC125 and R221239 complexed in RT, we de...
A novel 2-pyridinone scaffold was rationally designed and synthesized based on the active anti-HIV a...
In our continued efforts to discover more active and less toxic HIV-1 non-nucleoside reverse transcr...
A novel series of substituted piperazine-1-yl-pyrimidine derivatives were designed and synthesized a...
Based on crystallographic overlays of the known inhibitors TMC125 and R221239 complexed in RT, we de...
The development of new HIV-1 non-nucleoside reverse transcriptase inhibitors (NNRTIs) offers the pos...
On the basis of structural features, binding mode, and structure-activity relationship studies of tw...
A novel series of piperidin-4-yl-aminopyrimidine derivatives were designed fusing the pharmacophore ...
On the basis of structural features, binding mode, and structure-activity relationship studies of tw...
As a continuation of our efforts to discover and develop "me-better" drugs of DAPYs, novel diarylpyr...
Novel 2-aryalkylthio-4-amino-6-benzylpyrimidines (3a-i), which can be considered as S-DABO and TMC-1...
A series of 2-(4-(naphthalen-2-yl)-1,2,3-thiadiazol-5-ylthio)acetamide (TTA) derivatives were synthe...
Background: Despite the progress in the discovery of antiretroviral compounds for treating HIV-1 inf...
The present work is an extension of our ongoing efforts towards the development and identification o...
A series of novel 5-alkyl-6-Adamantylmethylpyrimidin-4(3H)-ones bearing various substituents at the ...
Based on crystallographic overlays of the known inhibitors TMC125 and R221239 complexed in RT, we de...
A novel 2-pyridinone scaffold was rationally designed and synthesized based on the active anti-HIV a...
In our continued efforts to discover more active and less toxic HIV-1 non-nucleoside reverse transcr...
A novel series of substituted piperazine-1-yl-pyrimidine derivatives were designed and synthesized a...
Based on crystallographic overlays of the known inhibitors TMC125 and R221239 complexed in RT, we de...
The development of new HIV-1 non-nucleoside reverse transcriptase inhibitors (NNRTIs) offers the pos...
On the basis of structural features, binding mode, and structure-activity relationship studies of tw...
A novel series of piperidin-4-yl-aminopyrimidine derivatives were designed fusing the pharmacophore ...
On the basis of structural features, binding mode, and structure-activity relationship studies of tw...
As a continuation of our efforts to discover and develop "me-better" drugs of DAPYs, novel diarylpyr...
Novel 2-aryalkylthio-4-amino-6-benzylpyrimidines (3a-i), which can be considered as S-DABO and TMC-1...
A series of 2-(4-(naphthalen-2-yl)-1,2,3-thiadiazol-5-ylthio)acetamide (TTA) derivatives were synthe...
Background: Despite the progress in the discovery of antiretroviral compounds for treating HIV-1 inf...